CXCR3 and neoplasm: Anti-CXCR3 treatment completely abrogated the attenuated tumor growth observed in GPR182−/− mice, suggesting that the improved anti-tumor immunity seen in GPR182−/− mice is dependent on the CXCL9/CXCL10/CXCR3 axis (Fig. 5d).